ShockWave Medical Q1 EPS $1.44 Beats $0.98 Estimate, Sales $218.81M Beat $207.69M Estimate
Portfolio Pulse from Benzinga Newsdesk
ShockWave Medical (NASDAQ:SWAV) exceeded Q1 earnings and sales estimates with EPS of $1.44 against a $0.98 forecast and sales of $218.81M versus an expected $207.69M. This represents a 39.81% and 35.85% increase in earnings and sales, respectively, compared to the same period last year.

May 06, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ShockWave Medical reported a significant beat on both earnings and sales estimates for Q1, with a notable year-over-year growth.
Beating earnings and sales estimates by a wide margin, especially with such significant year-over-year growth, is likely to instill investor confidence and could lead to a short-term uptick in SWAV's stock price. The substantial beat on both fronts highlights the company's strong performance and potential for future growth, making it an attractive asset for investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100